Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
Neurocrine Biosciences (Nasdaq: NBIX) will participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit on September 26, 2024. Chief Business Development and Strategy Officer and CEO-elect Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at 11:00 a.m. Eastern Time. The presentation will be webcast live and accessible on the company's website.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease-associated chorea, endometriosis, and uterine fibroids. The company has a robust pipeline with multiple compounds in mid- to late-phase clinical development.
Neurocrine Biosciences (Nasdaq: NBIX) parteciperà al 4° Summit Virtuale sui Nuovi Meccanismi in Neuropsichiatria di TD Cowen il 26 settembre 2024. Il Chief Business Development and Strategy Officer e CEO-designato Kyle Gano e il Vice-Presidente delle Relazioni con gli Investitori Todd Tushla presenteranno alle 11:00 ora orientale. La presentazione sarà trasmessa in diretta e accessibile sul sito web della compagnia.
Neurocrine Biosciences è una azienda biofarmaceutica focalizzata sulle neuroscienze dedicata allo sviluppo di trattamenti per disturbi neurologici, neuroendocrini e neuropsichiatrici. Il loro portafoglio include trattamenti approvati dalla FDA per la discinesia tardiva, la chorea associata alla malattia di Huntington, l'endometriosi e i fibromi uterini. L'azienda dispone di un solido pipeline con più composti in fase di sviluppo clinico intermedio e avanzato.
Neurocrine Biosciences (Nasdaq: NBIX) participará en la 4ª Cumbre Virtual sobre Nuevos Mecanismos en Neuropsiquiatría de TD Cowen el 26 de septiembre de 2024. El Director de Desarrollo de Negocios y Estrategia y CEO electo Kyle Gano y el Vicepresidente de Relaciones con Inversores Todd Tushla presentarán a las 11:00 a.m. hora del Este. La presentación será transmitida en vivo y accesible en el sitio web de la compañía.
Neurocrine Biosciences es una empresa biofarmacéutica centrada en las neurociencias dedicada al desarrollo de tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos. Su cartera incluye tratamientos aprobados por la FDA para la discinesia tardiva, la corea asociada a la enfermedad de Huntington, la endometriosis y los fibromas uterinos. La compañía cuenta con un robusto pipeline con múltiples compuestos en desarrollo clínico de fases intermedia a avanzada.
Neurocrine Biosciences (Nasdaq: NBIX)는 TD Cowen 제4회 가상 신경정신의학에서의 새로운 메커니즘 정상회의에 2024년 9월 26일에 참여합니다. 사업 개발 및 전략 책임자 겸 CEO 당선자 Kyle Gano와 투자자 관계 부사장 Todd Tushla가 동부 표준시 오전 11시에 발표할 예정입니다. 발표는 실시간으로 스트리밍될 것이며 회사 웹사이트에서 접근할 수 있습니다.
Neurocrine Biosciences는 신경과학 분야에 중점을 둔 생물의약품 회사로, 신경학적, 신경내분비, 신경정신 장애 치료제를 개발하는 데 전념하고 있습니다. 그들의 포트폴리오는 tardive dyskinesia, 헌팅턴병 관련 chorea, 자궁내막증 및 자궁 섬유종에 대한 FDA 승인 치료법을 포함합니다. 이 회사는 여러 가지 화합물이 중기에서 후기 임상 개발 단계에 있는 강력한 파이프라인을 보유하고 있습니다.
Neurocrine Biosciences (Nasdaq: NBIX) participera au 4ème Sommet Virtuel TD Cowen sur les Nouveaux Mécanismes en Neuropsychiatrie le 26 septembre 2024. Le Directeur du Développement Commercial et de la Stratégie et PDG élu Kyle Gano ainsi que le Vice-Président des Relations avec les Investisseurs Todd Tushla présenteront à 11h00, heure de l'Est. La présentation sera diffusée en direct et accessible sur le site web de l'entreprise.
Neurocrine Biosciences est une entreprise biopharmaceutique axée sur les neurosciences dédiée au développement de traitements pour les troubles neurologiques, neuroendocriniens et neuropsychiatriques. Leur portefeuille comprend des traitements approuvés par la FDA pour la dyskinésie tardive, la chorée associée à la maladie de Huntington, l'endométriose et les fibromes utérins. L'entreprise dispose d'un pipeline robuste avec plusieurs composés en développement clinique intermédiaire à avancé.
Neurocrine Biosciences (Nasdaq: NBIX) wird am 4. jährlichen virtuellen Gipfel zu neuen Mechanismen in der Neuropsychiatrie von TD Cowen am 26. September 2024 teilnehmen. Der Chief Business Development and Strategy Officer und designierte CEO Kyle Gano sowie der Vizepräsident für Investor Relations Todd Tushla werden um 11:00 Uhr Eastern Time präsentieren. Die Präsentation wird live übertragen und auf der Unternehmenswebsite zugänglich sein.
Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen, das sich auf Neurowissenschaften konzentriert und sich der Entwicklung von Behandlungen für neurologische, neuroendokrine und neuropsychiatrische Erkrankungen widmet. Ihr Portfolio umfasst von der FDA zugelassene Behandlungen für tardive Dyskinesie, chorea im Zusammenhang mit der Huntington-Krankheit, Endometriose und Uterusmyome. Das Unternehmen verfügt über eine robuste Pipeline mit mehreren Verbindungen in der mittleren bis späten klinischen Entwicklungsphase.
- None.
- None.
The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-the-td-cowen-4th-annual-novel-mechanisms-in-neuropsychiatry-virtual-summit-302253660.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When will Neurocrine Biosciences (NBIX) present at the TD Cowen Neuropsychiatry Summit?
Who will represent Neurocrine Biosciences (NBIX) at the TD Cowen Summit?
How can investors access Neurocrine Biosciences' (NBIX) presentation at the TD Cowen Summit?
What are some of the FDA-approved treatments in Neurocrine Biosciences' (NBIX) portfolio?
What is the focus of Neurocrine Biosciences' (NBIX) research and development?
